Merck to buy drug developer Pandion Therapeutics for $1.85 bln

Shares of Pandion rose 131.6% to a record high of $59.37 before the bell, while Merck shares were up about 1%. Pandion's lead drug candidate, PT101, met its main goals of safety and tolerability last month in an early-stage trial in patients with autoimmune diseases. Merck was represented by Credit Suisse Securities, Covington & Burling, while Centerview Partners LLC and Skadden, Arps, Slate, Meagher & Flom LLP represented Pandion.

Reuters | Updated: 25-02-2021 18:14 IST | Created: 25-02-2021 18:09 IST
Merck to buy drug developer Pandion Therapeutics for $1.85 bln
Representative image. Image Credit: Wikimedia

Merck & Co Inc said on Thursday it would buy drug developer Pandion Therapeutics Inc for about $1.85 billion in cash, expanding its portfolio of drugs that target autoimmune diseases.

The $60-per-share deal represents about 134% premium to Pandion's closing price on Wednesday. Shares of Pandion rose 131.6% to a record high of $59.37 before the bell, while Merck shares were up about 1%.

Pandion's lead drug candidate, PT101, met its main goals of safety and tolerability last month in an early-stage trial in patients with autoimmune diseases. In November, Merck agreed to buy privately-held VelosBio for $2.75 billion to strengthen its cancer drug portfolio as the drugmaker looks to reduce its reliance on its blockbuster cancer therapy Keytruda.

The deal between Merck and Pandion is expected to close in the first half of 2021, the companies said in a joint statement. Merck was represented by Credit Suisse Securities, Covington & Burling, while Centerview Partners LLC and Skadden, Arps, Slate, Meagher & Flom LLP represented Pandion.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Tracking Fintech during COVID-19: Harnessing power of technology

Its abundantly clear now that as fintech cements its place in the financial sector, accelerated further by the COVID-19 pandemic, it could open the sector to new possibilities by harnessing the power of technology to deliver financial ...

Tectonic turns: How technology shaped healthcare over the decades

Tracing an episodic evolution, with technology at the interface of human and his health....

World Water Day sees crises of inequality in countries both rich and poor

... ...

Privacy and data protection: Reviewing notable policy frameworks

The evolved privacy principles and the resulting legislation across the world primarily aim to force the data collector to define the purpose for which the data is being collected along with the need to obtain explicit consent for the said ...

Videos

Latest News

Argentine penguins waddle back to sea after rehab on dry land

Twelve black-and-white Magellanic penguins have been returned to the chilly seas off the Atlantic coast of Argentina after they were rescued suffering from issues including malnutrition and anemia and nursed back to health.The boot-high pen...

Biden calls for probe into Minnesota police shooting, warns against 'looting'

U.S. President Joe Biden on Monday called for protests over the fatal police shooting of a 20-year-old Black man in Minnesota to be peaceful and said a full-blown investigation is needed into the incident.A video Biden described as fairly g...

Cricket-Samson's century in vain as Punjab edge Rajasthan in IPL thriller

Rajasthan Royals Sanju Samson struck a blistering century in his first match as captain but was unable to prevent Punjab Kings from recording a four-run victory in a high-scoring Indian Premier League IPL thriller at the Wankhede Stadium on...

COVID SCIENCE-Autoimmune-disease drugs may reduce vaccine response; antibody treatments ineffective vs Brazil variant

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Autoimmune disease treatments may reduce vaccine response...

Give Feedback